Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 2;12(5):77. doi: 10.1038/s41408-022-00670-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — Among the 87 patients enrolled, 60 received doublet therapy and 27 received triplet therapy. In the doublet arm, hypomethylating agents (83%) and cladribine +/− low-dose cytarabine (17%) were used as low-intensity chemotherapy backbones. The most common FLT3 inhibitor in the doublet arm was sorafenib (60%), followed by quizartinib (27%), and midostaurin (13%). In the triplet arm, all patients received a hypomethylating agent (decitabine or azacitidine) as low-intensity chemotherapy backbone. Gilteritinib (44%) and sorafenib (37%) were the most common FLT3 inhibitors used in the triplet arm. ITD internal tandem domain, TKD tyrosine kinase domain; AML acute myeloid leukemia, FLT3i FLT3 inhibitor, VEN venetoclax.